Antitumor Virotherapy by Attenuated Measles Virus (MV)

doi:10.3390/biology2020587

. 2013 Mar 28;2(2):587-602.

doi: 10.3390/biology2020587.

Antitumor Virotherapy by Attenuated Measles Virus (MV)

Jean-Baptiste Guillerme¹, Marc Gregoire², Frédéric Tangy³, Jean-François Fonteneau⁴

Affiliations

¹ INSERM, UMR892, Nantes, F-44000, France. jean-baptiste.guillerme@univ-nantes.fr.
² INSERM, UMR892, Nantes, F-44000, France. marc.gregoire@nantes.inserm.fr.
³ CNRS, URA3015, Institut Pasteur, Unité de Génomique Virale et Vaccination, Paris, 75015, France. ftangy@pasteur.fr.
⁴ INSERM, UMR892, Nantes, F-44000, France. jean-francois.fonteneau@inserm.fr.

PMID: 24832799
PMCID: PMC3960896
DOI: 10.3390/biology2020587

Antitumor Virotherapy by Attenuated Measles Virus (MV)

Jean-Baptiste Guillerme et al. Biology (Basel). 2013.

. 2013 Mar 28;2(2):587-602.

doi: 10.3390/biology2020587.

Authors

Jean-Baptiste Guillerme¹, Marc Gregoire², Frédéric Tangy³, Jean-François Fonteneau⁴

Affiliations

¹ INSERM, UMR892, Nantes, F-44000, France. jean-baptiste.guillerme@univ-nantes.fr.
² INSERM, UMR892, Nantes, F-44000, France. marc.gregoire@nantes.inserm.fr.
³ CNRS, URA3015, Institut Pasteur, Unité de Génomique Virale et Vaccination, Paris, 75015, France. ftangy@pasteur.fr.
⁴ INSERM, UMR892, Nantes, F-44000, France. jean-francois.fonteneau@inserm.fr.

PMID: 24832799
PMCID: PMC3960896
DOI: 10.3390/biology2020587

Abstract

Antitumor virotherapy consists of the use of replication-competent viruses to infect and kill tumor cells preferentially, without damaging healthy cells. Vaccine-attenuated strains of measles virus (MV) are good candidates for this approach. Attenuated MV uses the CD46 molecule as a major entry receptor into cells. This molecule negatively regulates the complement system and is frequently overexpressed by cancer cells to escape lysis by the complement system. MV exhibits oncolytic properties in many cancer types in vitro, and in mouse models. Phase I clinical trials using MV are currently underway. Here, we review the state of this therapeutic approach, with a focus on the effects of MV on the antitumor immune response.

PubMed Disclaimer

Cited by

Oncolysis by paramyxoviruses: preclinical and clinical studies.
Matveeva OV, Guo ZS, Senin VM, Senina AV, Shabalina SA, Chumakov PM. Matveeva OV, et al. Mol Ther Oncolytics. 2015;2:15017-. doi: 10.1038/mto.2015.17. Epub 2015 Oct 21. Mol Ther Oncolytics. 2015. PMID: 26640815 Free PMC article.
Oncolytic immunotherapy: The new clinical outbreak.
Fonteneau JF, Achard C, Zaupa C, Foloppe J, Erbs P. Fonteneau JF, et al. Oncoimmunology. 2015 Aug 12;5(1):e1066961. doi: 10.1080/2162402X.2015.1066961. eCollection 2016. Oncoimmunology. 2015. PMID: 26942085 Free PMC article. No abstract available.
Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46 mice.
Pliquet E, Ruffie C, Escande M, Thalmensi J, Najburg V, Combredet C, Bestetti T, Julithe M, Liard C, Huet T, Wain-Hobson S, Tangy F, Langlade-Demoyen P. Pliquet E, et al. Cancer Immunol Immunother. 2019 Apr;68(4):533-544. doi: 10.1007/s00262-018-2272-3. Epub 2019 Jan 17. Cancer Immunol Immunother. 2019. PMID: 30656384 Free PMC article.
Repurposing Infectious Diseases Vaccines Against Cancer.
Vandeborne L, Pantziarka P, Van Nuffel AMT, Bouche G. Vandeborne L, et al. Front Oncol. 2021 May 13;11:688755. doi: 10.3389/fonc.2021.688755. eCollection 2021. Front Oncol. 2021. PMID: 34055652 Free PMC article. Review.
Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells.
Achard C, Guillerme JB, Bruni D, Boisgerault N, Combredet C, Tangy F, Jouvenet N, Grégoire M, Fonteneau JF. Achard C, et al. Oncoimmunology. 2016 Nov 18;6(1):e1261240. doi: 10.1080/2162402X.2016.1261240. eCollection 2017. Oncoimmunology. 2016. PMID: 28197384 Free PMC article.

See all "Cited by" articles

References

1. Boisgerault N., Tangy F., Gregoire M. New perspectives in cancer virotherapy: Bringing the immune system into play. Immunotherapy. 2010;2:185–199. doi: 10.2217/imt.10.6. - DOI - PubMed
1. Russell S.J., Peng K.W., Bell J.C. Oncolytic virotherapy. Nat. Biotechnol. 2012;30:658–670. doi: 10.1038/nbt.2287. - DOI - PMC - PubMed
1. Mogensen T.H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 2009;22:240–273. doi: 10.1128/CMR.00046-08. Table of Contents. - DOI - PMC - PubMed
1. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 1998;392:245–252. doi: 10.1038/32588. - DOI - PubMed
1. Bluming A.Z., Ziegler J.L. Regression of burkitt’s lymphoma in association with measles infection. Lancet. 1971;2:105–106. - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Boisgerault N., Tangy F., Gregoire M. New perspectives in cancer virotherapy: Bringing the immune system into play. Immunotherapy. 2010;2:185–199. doi: 10.2217/imt.10.6. - DOI - PubMed

[2] Boisgerault N., Tangy F., Gregoire M. New perspectives in cancer virotherapy: Bringing the immune system into play. Immunotherapy. 2010;2:185–199. doi: 10.2217/imt.10.6. - DOI - PubMed

[3] Russell S.J., Peng K.W., Bell J.C. Oncolytic virotherapy. Nat. Biotechnol. 2012;30:658–670. doi: 10.1038/nbt.2287. - DOI - PMC - PubMed

[4] Russell S.J., Peng K.W., Bell J.C. Oncolytic virotherapy. Nat. Biotechnol. 2012;30:658–670. doi: 10.1038/nbt.2287. - DOI - PMC - PubMed

[5] Mogensen T.H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 2009;22:240–273. doi: 10.1128/CMR.00046-08. Table of Contents. - DOI - PMC - PubMed

[6] Mogensen T.H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 2009;22:240–273. doi: 10.1128/CMR.00046-08. Table of Contents. - DOI - PMC - PubMed

[7] Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 1998;392:245–252. doi: 10.1038/32588. - DOI - PubMed

[8] Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 1998;392:245–252. doi: 10.1038/32588. - DOI - PubMed

[9] Bluming A.Z., Ziegler J.L. Regression of burkitt’s lymphoma in association with measles infection. Lancet. 1971;2:105–106. - PubMed

[10] Bluming A.Z., Ziegler J.L. Regression of burkitt’s lymphoma in association with measles infection. Lancet. 1971;2:105–106. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Antitumor Virotherapy by Attenuated Measles Virus (MV)

Affiliations

Antitumor Virotherapy by Attenuated Measles Virus (MV)

Authors

Affiliations

Abstract

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Similar articles

Cited by

References

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources